Skip to main content
. 2022 Mar 15;43(10):2636–2650. doi: 10.1038/s41401-022-00889-4

Fig. 2. Sotagliflozin promotes angiogenic factors expression in skeletal muscle cells under hyperglycemia.

Fig. 2

a mRNA expression levels of angiogenic factors in C2C12 cells treated with sotagliflozin under hyperglycemia, as examined using quantitative reverse-transcribed PCR (qRT-PCR). b, c Protein expression levels of angiogenic factors in C2C12 cells treated with sotagliflozin under hyperglycemia, as examined using Western blotting. Representative images (b) and quantification results (c) were shown. d, e Protein expression levels of angiogenic factors in C2C12 cells treated with different doses of sotagliflozin under hyperglycemia, as examined using Western blotting. Representative images (d) and quantification results (e) were shown. f Secreted amount of VEGF-A and PDGF-BB in the culture medium of matured C2C12 cells treated with sotagliflozin under hyperglycemia, as analyzed using ELISA. Cells cultured under normoglycemia were used as controls. β‐Actin was used for qRT-PCR normalization and as Western blotting loading control. Quantitative data are shown as relative values to those of control, and expressed as mean ± SD (n = 3). NG normoglycemia, HG hyperglycemia, HG + Sota hyperglycemia + sotagliflozin, NS not significant; *P < 0.05; **P < 0.01; ***P < 0.001.